Latest revenue
$3.2M
as of 2026-03-31
Latest net income
$-18.3M
as of 2026-03-31
Net margin
-567.9%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AKTS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.01B
- Enterprise value
- $636.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.99×
- Dividend yield
- 0.0%
- 52-wk high
- $29.16
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 53.4M
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors. These leading products, which target prostate specific membrane antigen or somatostatin-2 receptor, are each currently approved in only one tumor type, yet have seen considerable commercial uptake and have become fundamental…
AI summary unavailable — showing raw filing excerpt
Generated from AKTS's filing dated 2026-03-30
Key risks
Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below, as well as the other information in this Annual Report, including our consolidated financial statements and the related notes appearing elsewhere in this Annual Report and the sections of this Annual Report titled “Special Note Regarding Forward-Looking Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” before you make an investment decision in our common stock. The risks described below are not the only risks that we face. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that…
AI summary unavailable — showing raw filing excerpt
Generated from AKTS's filing dated 2026-03-30
Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $3.2M | +123.0% | $-18.3M | -22.3% | -567.9% |
Q1 2025 2025-03-31 | $1.4M | — | $-15.0M | — | -1035.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AKTS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$114.3M
Insider selling
$0
Net activity
+$114.3M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AKTS
Institutional value
$94.9M
Total shares held
5.3M
Distinct holders
29
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2.1M | $37.8M | — | New |
| 2 | Merck & Co., Inc. | 952.8K | $17.0M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 833.9K | $14.9M | — | New |
| 4 | Avidity Partners Management LP | 468.6K | $8.8M | — | New |
| 5 | UBS Group AG | 353.3K | $6.3M | — | New |
| 6 | VANGUARD FIDUCIARY TRUST CO | 127.4K | $2.3M | — | New |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 120.3K | $2.2M | — | New |
| 8 | TD ASSET MANAGEMENT INC | 101.0K | $1.8M | — | New |
| 9 | Bank of New York Mellon Corp | 42.9K | $767.5K | — | New |
| 10 | SEVEN GRAND MANAGERS, LLC | 25.0K | $447.3K | — | New |
| 11 | Nuveen, LLC | 24.5K | $437.7K | — | New |
| 12 | RHUMBLINE ADVISERS | 21.0K | $376.3K | — | New |
| 13 | Universal- Beteiligungs- und Servicegesellschaft mbH | 14.2K | $253.8K | — | New |
| 14 | DEUTSCHE BANK AG\ | 14.1K | $251.9K | — | New |
| 15 | Invesco Ltd. | 12.1K | $216.7K | — | New |
| 16 | Vanguard Global Advisers, LLC | 9.7K | $173.3K | — | New |
| 17 | JPMORGAN CHASE & CO | 8.4K | $138.2K | — | New |
| 18 | WELLS FARGO & COMPANY/MN | 7.6K | $136.2K | — | New |
| 19 | PNC Financial Services Group, Inc. | 6.8K | $122.2K | — | New |
| 20 | Police & Firemen's Retirement System of New Jersey | 5.5K | $98.9K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AKTS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.